NCT02859103View on ClinicalTrials.gov

Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Pre- and Post-Desvenlafaxine Treatment

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

November 4, 2019

Study Completion Date

November 4, 2019

Conditions

DepressionAnhedonia

Interventions

DRUG

Desvenlafaxine

Patients will be provided 50mg dose of desvenlafaxine for 1 week titrated up to 100mg dose of desvenlafaxine for 7 weeks.

Trial Locations (1)

M5B 1M8

St. Michael's Hospital, Toronto

All Listed Sponsors

lead

Unity Health Toronto

OTHER

NCT02859103 - Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Pre- and Post-Desvenlafaxine Treatment | Biotech Hunter | Biotech Hunter